MétaCan
Menu
Back to cohort
Record W1978278516 · doi:10.4088/jcp.12084su1c.03

Using Measurement Strategies to Identify and Monitor Residual Symptoms

2013· review· en· W1978278516 on OpenAlexaffabout
Roger S. McIntyre

Bibliographic record

VenueThe Journal of Clinical Psychiatry · 2013
Typereview
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsUniversity of Toronto
FundersH. Lundbeck A/SStanley Medical Research InstituteNational Alliance for Research on Schizophrenia and DepressionGlaxoSmithKlinePfizerTakeda Pharmaceuticals InternationalAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsMajor depressive disorderAntidepressantCognitionQuality of life (healthcare)PharmacotherapyResidualMedicineVortioxetinePsychiatryCognitive behavioral therapyIntervention (counseling)Depression (economics)Clinical psychologyPsychologyPsychotherapistAnxiety

Abstract

fetched live from OpenAlex

Article AbstractMajor depressive disorder (MDD) is a persistent, pervasive, and chronic disorder that significantly affects patients†functioning and quality of life. Most patients treated for MDD continue to have residual symptoms after acute treatment with pharmacotherapy. One of the most commonly encountered residual symptoms is cognitive dysfunction, which substantially affects patient outcomes. While antidepressant monotherapy is an effective first-line treatment for some patients with MDD, patients with residual symptoms (eg, cognitive dysfunction) will require an additional treatment intervention such as augmentation or switch to an alternative treatment strategy. Measurement-based care has been demonstrated to improve patient outcomes in MDD. The clinical importance of cognitive dysfunction in MDD invites the need to probe, screen, and measure the extent of cognitive impairment. (J Clin Psychiatry 2013;74:14-18) From the Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. This article is derived from the planning teleconference series "Depression: Managing the Full Range of Symptoms to Achieve Lasting Remission," which was held in May and June 2013 and supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Lundbeck. Dr McIntyre has served on the advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, France Foundation, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck, Organon, Pfizer, and Shire; has served on the speakers bureaus for AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, Merck, and Pfizer; has received grant/research support from AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, the National Alliance for Research on Schizophrenia and Depression, the National Institutes of Mental Health, Pfizer, Shire, and the Stanley Medical Research Institute; and has participated in CME activities for AstraZeneca, Bristol-Myers Squibb, CME Outfitters, Eli Lilly, France Foundation, I3CME, Merck, Optum Health, and Pfizer. Corresponding author: Roger S. McIntyre, MD, 399 Bathurst St, MP 9-325, Toronto, Ontario, M5T 2S8, Canada (roger.mcintyre@uhn.on.ca). doi:10.4088/JCP.12084su1c.03 © Copyright 2013 Physicians Postgraduate Press, Inc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.053
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.015
Threshold uncertainty score0.079

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0150.053
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0040.003
Science and technology studies0.0010.001
Scholarly communication0.0040.003
Open science0.0020.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.381
GPT teacher head0.557
Teacher spread0.177 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations27
Published2013
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of Clinical PsychiatrySame topicTreatment of Major DepressionFrench-language works237,207